French get a break

Bioprocessing play Deinove S.A. is the second biotech in as many weeks to go public on Alternext Paris, following autoimmune and inflammation company Neovacs S.A. Both IPOs have benefitted from French tax incentives designed to encourage investment in small companies.

The environment on Alternext Paris has improved, although it's not yet a fully open IPO window, argued Philippe Pouletty of Truffle Capital - which invested in both companies...